Mutations within exons 12–15 of SF3B1, encoding the C-terminal portion of the protein, have been described in 20% of uveal melanoma, 19% of CLL and 1.8% of breast cancers [20, 22, 30]. This evidence concerns the gene SF3B1 and breast carcinoma.